Efgartigimod Alfa
Efgartigimod alfa is an immunotherapy designed to reduce pathogenic IgG antibodies in the body by blocking the neonatal Fc receptor (FcRn). It is coformulated with hyaluronidase as VYVGART HYTRULO for subcutaneous administration and is used to treat autoimmune conditions driven by harmful IgG antibodies.
Efgartigimod alfa reduces harmful IgG antibodies by targeting FcRn and is used for autoimmune diseases.
Key facts at a glance
- ATC
- L04AA58
- RxNorm
- 2587717
- Generic
- Efgartigimod Alfa
- Class
- atc-l04
- Brands
- Vyvgart, Vyvgart Hytrulo
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection, prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 10mg/kg
- Maximum
- consult physician
- Frequency
- once weekly for 4 weeks (induction), then individualized maintenance
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
use only if potential benefits outweigh potential risks to fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
use only if potential benefits outweigh potential risks to fetus
regular fetal monitoring and growth assessments
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
consider timing of last dose before delivery due to potential neonatal exposure
close monitoring of newborn for potential FcRn-mediated effects
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
discontinue breastfeeding or discontinue drug based on benefit-risk assessment
monitor infant for signs of infection or immunological effects
Use with caution and monitor for adverse effects.
geriatric
elderlyno adjustment needed
no dose adjustment required based on age alone; monitor for infections
routine monitoring for infectious complications
pediatric_age
children adolescentsnot established
not approved for use in patients under 18 years of age
not applicable
renal_impairment
mild to moderateno adjustment needed
no dose adjustment required for mild to moderate renal impairment
routine clinical monitoring
renal_impairment
severeuse with caution
limited data in severe renal impairment; use with caution
enhanced clinical monitoring recommended
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateuse with caution
not specifically studied; use with caution in hepatic impairment
routine clinical monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
severeuse with caution
not studied; use only if benefits outweigh risks
enhanced clinical monitoring recommended
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Mechanism of action classification
FDA approval year
FDA approval information for Vyvgart
Primary indication
Therapeutic indication
Mechanism of action
Pharmacological mechanism
Used to treat autoimmune conditions where pathogenic IgG antibodies contribute to disease, such as generalized myasthenia gravis (gMG). Treatment should be initiated by healthcare providers experienced in managing these conditions.
Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing IgG recycling and leading to reduced circulating IgG levels. The hyaluronidase component enables subcutaneous administration by increasing tissue permeability.
As an immunomodulatory therapy, it affects IgG antibody levels systemically. Patients should be monitored for infections during treatment. May interact with other IgG-based therapies. Must be administered by healthcare professionals. Patients should report signs of infection or allergic reactions promptly.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy